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Valentin Fuster, MD, PHDI n Book II of Aristotle’s Nicomachean Ethics, theGreek philosopher famously stated that everyactivity aims at some end, and he further
deﬁned man’s virtues as a means to the ultimate
end: happiness (1). This has spawned centuries of
debate over whether the end justiﬁes the means to
achieve those goals. Health care providers today are
being challenged by 3 goals or objectives: to improve
the delivery and experience of care, to improve the
health of populations, and to reduce the per capita
costs (2). If this is our prescribed “end,” then technol-
ogy may provide a means of achieving those goals—
but not without the assistance of experienced,
thoughtful, and valued clinicians.
WHY FOCUS ON
CARDIOVASCULAR DISEASE GOALS?
By 2005, the total number of cardiovascular disease
(CVD) deaths (mainly coronary heart disease, stroke,
and rheumatic heart disease) had increased globally
to 17.5 million from 14.4 million in 1990 (3). Of these,
7.6 million were attributed to coronary heart disease
and 5.7 million to stroke. More than 80% of the deaths
occurred in low- and middle-income countries (3). As
cardiovascular (CV) specialists, we are exposed to the
number 1 killer in the world, so our practices have to
be changed under the new mandate to fulﬁll 2 of the
previously mentioned goals: improve the delivery of
care and the health of populations. But what about
the third objective of reducing costs? The economic
cost of treating these diseases is staggering. In 2010,
the total costs of CVD (heart disease and stroke) in the
United States were estimated to be $444 billion (4).
Treatment of these diseases accounts for about $1 of. Wiener Cardiovascular Institute, Icahn
inai, New York, New York.every $6 spent on health care in this country, ac-
cording to the Centers for Disease Control and Pre-
vention (4). A large proportion of these costs occurs
in the hospital setting. In 2003, heart disease as a
ﬁrst-listed diagnosis was the highest-ranked disease
category for hospital discharges, representing a 31%
increase over discharges in 1979 (5). In fact, an anal-
ysis of hospital discharge data for 1979 to 2003
showed sizable increases in hospitalization for major
CV diseases, including coronary heart disease (16%),
stroke (29%), and chronic heart failure (17%) (6).
Thus, the scrutiny will only intensify on our specialty,
because the stakes are very high and the need for
change is great.
WHAT ARE THE MEANS TO
ACHIEVE THE GOALS?
We are already experiencing a signiﬁcant change
in the way we deliver CV medicine. There is far
more ambulatory care delivered, and this trend will
continue to grow, even with patients who are post-
short hospitalization and who will be monitored in
their home. We will see a rise in at-home visits from
care teams, with a particular reliance upon nurses and
nurse practitioners.
Hospitalizations will only occur for emergent is-
sues or for interventional procedures with a short
hospital stay. Thus, there is a need for the CV spe-
cialists and health care workers to have more training
in ambulatory and home-based care, as well as
training on the wireless electronic systems that will
be used to monitor their patients. These electronic
systems will become an invaluable part of the care
team, as they will monitor the vital signs of the pa-
tients and integrate the present-day data with the
makeup of the individual: organ related, metabolic,
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482highly trained clinician to receive these data and
act on the information. Indeed, technology will not
replace the need for experienced, thoughtful, and
valued clinicians. Today, CV specialists must rely on
patient contact, where we gather an essential
behavioral and emotional understanding of the in-
dividual, which helps us in their management. We
still need to understand that every individual or
patient is different, and many unique factors need
to be considered to achieve the optimal outcomes.
We rely on our knowledge and experience, our
intuitive understanding, as well as our legacy
knowledge of patient care.
HOW SPECIFICALLY CAN WE ACHIEVE
AND IMPLEMENT THE GOALS?
As mentioned, the roles and training of the CV spe-
cialists and other members of the health care system
will signiﬁcantly move toward practicing in the
ambulatory and home-based setting and toward
rapidly integrating evolving knowledge via contin-
uous education through different means of commu-
nication. Speciﬁcally, the spectrum of patients that
CV specialists and health care givers will treat can be
outlined in a longitudinal fashion from birth to aging
and within the focus of 4 layers (Figure 1): acute
coronary and cerebrovascular syndromes, stable CV
disease, subclinical CV disease, and health promo-
tion. Such personnel will have the aid of predictive
analytics technologies, such as Watson Health (IBM,ty of Cardiovascular Care
that CV specialists and health care givers will treat can be outlined in
n from birth to aging and within the focus of 4 layers.Armonk, New York), that will be continuously gath-
ering health-related data of individuals.
IBM research indicates that the average person is
likely to generate >1 million gigabytes of health-
related data in a lifetime, which is the equivalent of
300 million books (7). These types of tools, along with
genomics and genetics, will drive more of our effort
into the health promotion stage of care, as opposed to
simply treating the symptoms once they have man-
ifested into clinical disease. It is with the assistance of
these technologies in health promotion that the CV
health care givers will have the greatest effect in the
future, which means starting with individuals at a
much younger age. In fact, our research in this area
has shown that we can have the greatest effect on
health from ages 3 to 6 years (8,9). From ages 20 to 50
years, the identiﬁcation of subclinical disease
through noninvasive and affordable imaging tech-
nology may be the main opportunity or door of entry
to implement a modiﬁcation of lifestyle before the
disease has manifested (10,11). However, when dis-
ease does present itself, for example at ages 50 to 80
years, a combination of qualiﬁed clinicians and
remote technologies will track these patients in an
ambulatory setting if they have stable CV disease or in
their homes after a short hospitalization for an acute
coronary or cerebrovascular event. No longer will
patients be hospitalized for long periods of time. This
will be helpful in reducing the tremendous costs of
CV disease in the in-hospital setting. It will also
reduce the size of hospitals in the future. Impor-
tantly, this transition will have tremendous implica-
tions in the need for additional training in ambulatory
services, which is clearly outlined in Core Cardio-
vascular Training Statement 4: Task Force 1, pub-
lished in May 2015 in the Journal (12).
If we all agree that our best “end” is the triple aim of
health care—to improve the delivery and experience
of care, to improve the health of populations, and to
reduce the per capita costs—we cannot resist the
changes, or means, that are needed to achieve that
end. Thoughtful, well-prepared clinicians, armed
with the data generated by varied technologies,
particularly wireless, will drive this change.
“Every action and pursuit is thought to aim at
some good, and for this reason the good has been
declared to be that at which all things aim.”
—Aristotle (13)
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